J Korean Med Sci.  2022 Jul;37(29):e242. 10.3346/jkms.2022.37.e242.

Is Longer Duration or Higher Dose of Steroid Use Effective in Critical COVID-19 Patients?: An Area of Uncertainty

• Choi WS

• KMID: 2532092
• DOI: http://doi.org/10.3346/jkms.2022.37.e242

Reference

1. RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8):693–704. PMID: 32678530.

2. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Updated 2022. Accessed July 18, 2022.

3. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Updated 2022. Accessed July 18, 2022. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management .

4. Oh SM, Ham SY, Suh HJ, Lee E, Park SW. Clinical characteristics of COVID-19: use of steroids in mostly unvaccinated COVID-19 patients before the omicron variant. J Korean Med Sci. 2022; 37(29):e228.

5. Maskin LP, Bonelli I, Olarte GL, Palizas F Jr, Velo AE, Lurbet MF, et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomized open-label clinical trial. J Intensive Care Med. 2022; 37(4):491–499. PMID: 34898320.